Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Lineage Cell Therapeutics (LCTX) Tops Q4 EPS by 2c, Revenues Beat

March 12, 2020 4:46 PM EDT

Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $1.24 million versus the consensus estimate of $1.03 million.

2019 was a transformative year for Lineage. We established Lineage as a leading cell therapy company with the goal to usher in a new branch of medicine based on transplanting intact cells into the body... More